Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 26, 2021

Coronavirus company news summary – Therma Bright moves to Health Canada approval for Covid-19 antigen kit – Thermo Fisher completes FDA listing and launches the qPCR platform for Covid-19 testing

By Chloe Kent

Therma Bright has submitted an application to Health Canada seeking approval to conduct a clinical study for its AcuVid Covid-19 Rapid Antigen Saliva Test. The company already received institutional review board (IRB) approval from the US Food and Drug Administration (FDA).

1health, a testing as a service (TaaS) company, and The Vitamin Shoppe have announced that they have collaborated to make available a simple, self-administered test for US consumers nationwide. Under the agreement, the tests will now commercially available for sale on The Vitamin Shoppe’s site.

Thermo Fisher Scientific has completed FDA listing for the Applied Biosystems QuantStudio 5 Dx Real-Time PCR system. The system allows clinical laboratories and assay developer to meet testing demands more efficiently and enhance their molecular diagnostics workflows. The system’s simplified, efficient workflow minimizes steps to deliver quality results in as little as 30 minutes. The system has high sensitivity and specificity and offers up to six channels for multiplexing.

Related Companies

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy